Revance Therapeutics Inc (RVNC)
4.17
-0.14
(-3.25%)
USD |
NASDAQ |
Nov 15, 16:00
4.175
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Research and Development Expense (TTM): 77.24M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 77.24M |
| June 30, 2024 | 74.55M |
| March 31, 2024 | 76.27M |
| December 31, 2023 | 79.41M |
| September 30, 2023 | 63.38M |
| June 30, 2023 | 80.80M |
| March 31, 2023 | 88.09M |
| December 31, 2022 | 101.29M |
| September 30, 2022 | 111.21M |
| June 30, 2022 | 115.20M |
| March 31, 2022 | 119.73M |
| December 31, 2021 | 116.26M |
| September 30, 2021 | 116.56M |
| June 30, 2021 | 115.59M |
| March 31, 2021 | 113.25M |
| December 31, 2020 | 125.80M |
| September 30, 2020 | 123.52M |
| June 30, 2020 | 120.24M |
| March 31, 2020 | 118.66M |
| December 31, 2019 | 102.86M |
| September 30, 2019 | 100.90M |
| June 30, 2019 | 96.90M |
| March 31, 2019 | 94.25M |
| Date | Value |
|---|---|
| December 31, 2018 | 92.49M |
| September 30, 2018 | 87.96M |
| June 30, 2018 | 87.76M |
| March 31, 2018 | 83.19M |
| December 31, 2017 | 80.36M |
| September 30, 2017 | 71.89M |
| June 30, 2017 | 60.54M |
| March 31, 2017 | 57.43M |
| December 31, 2016 | 50.38M |
| September 30, 2016 | 52.81M |
| June 30, 2016 | 55.53M |
| March 31, 2016 | 50.64M |
| December 31, 2015 | 47.53M |
| September 30, 2015 | 41.70M |
| June 30, 2015 | 37.29M |
| March 31, 2015 | 35.09M |
| December 31, 2014 | 33.39M |
| September 30, 2014 | 30.50M |
| June 30, 2014 | 28.18M |
| March 31, 2014 | 27.86M |
| December 31, 2013 | 27.83M |
| September 30, 2013 | 38.47M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
63.38M
Minimum
Sep 2023
125.80M
Maximum
Dec 2020
102.00M
Average
112.23M
Median
Research and Development Expense (TTM) Benchmarks
| Recursion Pharmaceuticals Inc | 285.57M |
| Regeneron Pharmaceuticals Inc | 4.897B |
| MEI Pharma Inc | 16.56M |
| GlycoMimetics Inc | 22.89M |
| Anebulo Pharmaceuticals Inc | 3.549M |